Bisphosphonate-related Osteonecrosis of the Jaw in Metastatic Breast Cancer Patients: a Review of 25 Cases

Overview

Journal Maxillofac Plast Reconstr Surg

Publisher Springer Nature

Date 2016 Feb 13

PMID 26870717

Citations 6

Authors

Hong-Joon Kim

Tae-Jun Park

Kang-Min Ahn

Affiliations

Soon will be listed here.

Abstract

Background: Intravenous bisphosphonates have been used in metastatic breast cancer patients to reduce pathologic bone fracture and bone pain. However, necrosis of the jaw has been reported in those who received intravenous bisphosphonates. Bisphosphonate-related osteonecrosis of the jaw (BRONJ) is caused by dental extraction, dental implant surgery, and denture wearing; however, it occurs spontaneously. The purpose of this study was to report BRONJ in metastatic breast cancer patients.

Methods: Consecutive 25 female patients were referred from the Department of Oncology from 2008 to 2014 for jaw bone discomfort. Staging of breast cancer, history of bisphosphonate infusion, etiology of BRONJ, and treatment results were reviewed. Average age of the patients was 55.4 years old (38-74). Twelve maxillae and 16 mandibles were involved. Conservative treatments such as irrigation, antibiotic medication, analgesics, and oral gargle were applied for all patients for the initial treatment. Patients who had sequestrum underwent debridement and primary closure.

Results: The etiologies of BRONJ were dental extraction (19 cases), dental implant (2 cases), and endodontic treatment (1 case). However, three patients did not have any risk factors to cause BRONJ. Three patients died of progression of metastasis during follow-up periods. Surgical debridement was performed in 21 patients with success in 18 patients. Three patients showed recurred bone exposure and infection after operation.

Conclusions: Prevention of the BRONJ is critical in metastatic breast cancer patients. Conservative treatment to reduce pain, discomfort, and infection is recommended for the initial therapy. However, if there is a sequestrum, surgical debridement and primary closure is the key to treat the BRONJ.

Citing Articles

Mechanism of bisphosphonate-related osteonecrosis of the jaw (BRONJ) revealed by targeted removal of legacy bisphosphonate from jawbone using competing inert hydroxymethylene diphosphonate.

Okawa H, Kondo T, Hokugo A, Cherian P, Campagna J, Lentini N Elife. 2022; 11.

PMID: 36017995 PMC: 9489207. DOI: 10.7554/eLife.76207.

Clinical profile of individuals with bisphosphonate-related osteonecrosis of the jaw: an integrative review.

Maciel A, Quispe R, Martins L, Caldas R, Santos P Sao Paulo Med J. 2020; 138(4):326-335.

PMID: 32725058 PMC: 9673834. DOI: 10.1590/1516-3180.2019.0352.r2.15052020.

Overall and disease-specific survival outcomes following primary surgery for oral squamous cell carcinoma: analysis of consecutive 67 patients.

Sim Y, Hwang J, Ahn K J Korean Assoc Oral Maxillofac Surg. 2019; 45(2):83-90.

PMID: 31106136 PMC: 6502750. DOI: 10.5125/jkaoms.2019.45.2.83.

Mindfulness-Based Stress Reduction on breast cancer symptoms: systematic review and meta-analysis.

Castanhel F, Liberali R Einstein (Sao Paulo). 2018; 16(4):eRW4383.

PMID: 30540032 PMC: 6282865. DOI: 10.31744/einstein_journal/2018RW4383.

Clinical characteristics and recurrence-related factors of medication-related osteonecrosis of the jaw.

Kang M, Lee D, Kim C, Song I, Jun S J Korean Assoc Oral Maxillofac Surg. 2018; 44(5):225-231.

PMID: 30402414 PMC: 6209697. DOI: 10.5125/jkaoms.2018.44.5.225.

References

Rodan G, Fleisch H . Bisphosphonates: mechanisms of action. J Clin Invest. 1996; 97(12):2692-6. PMC: 507360. DOI: 10.1172/JCI118722. View

Matsuo A, Hamada H, Takahashi H, Okamoto A, Kaise H, Chikazu D . Evaluation of dental implants as a risk factor for the development of bisphosphonate-related osteonecrosis of the jaw in breast cancer patients. Odontology. 2015; 104(3):363-71. DOI: 10.1007/s10266-015-0207-4. View

Mashiba T, Hirano T, Turner C, Forwood M, JOHNSTON C, Burr D . Suppressed bone turnover by bisphosphonates increases microdamage accumulation and reduces some biomechanical properties in dog rib. J Bone Miner Res. 2000; 15(4):613-20. DOI: 10.1359/jbmr.2000.15.4.613. View

Nomura T, Shibahara T, Uchiyama T, Yamamoto N, Shibui T, Yakushiji T . Bisphosphonate-related osteonecrosis of jaw (BRONJ) in Japanese population: a case series of 13 patients at our clinic. Bull Tokyo Dent Coll. 2013; 54(2):117-25. DOI: 10.2209/tdcpublication.54.117. View

Coleman R . Optimising treatment of bone metastases by Aredia(TM) and Zometa(TM). Breast Cancer. 2000; 7(4):361-9. DOI: 10.1007/BF02966406. View

Ruggiero S, Dodson T, Fantasia J, Goodday R, Aghaloo T, Mehrotra B . American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw--2014 update. J Oral Maxillofac Surg. 2014; 72(10):1938-56. DOI: 10.1016/j.joms.2014.04.031. View

Gnant M, Dubsky P, Hadji P . Bisphosphonates: prevention of bone metastases in breast cancer. Recent Results Cancer Res. 2012; 192:65-91. DOI: 10.1007/978-3-642-21892-7_3. View

Drake M, Cremers S . Bisphosphonate therapeutics in bone disease: the hard and soft data on osteoclast inhibition. Mol Interv. 2010; 10(3):141-52. DOI: 10.1124/mi.10.3.5. View

Woo S, Hellstein J, Kalmar J . Narrative [corrected] review: bisphosphonates and osteonecrosis of the jaws. Ann Intern Med. 2006; 144(10):753-61. DOI: 10.7326/0003-4819-144-10-200605160-00009. View

10.

Hughes D, MacDonald B, Russell R, Gowen M . Inhibition of osteoclast-like cell formation by bisphosphonates in long-term cultures of human bone marrow. J Clin Invest. 1989; 83(6):1930-5. PMC: 303914. DOI: 10.1172/JCI114100. View

11.

Gnant M, Mlineritsch B, Luschin-Ebengreuth G, Kainberger F, Kassmann H, Piswanger-Solkner J . Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy. Lancet Oncol. 2008; 9(9):840-9. DOI: 10.1016/S1470-2045(08)70204-3. View

12.

Bundred N . Antiresorptive therapies in oncology and their effects on cancer progression. Cancer Treat Rev. 2012; 38(6):776-86. DOI: 10.1016/j.ctrv.2012.02.002. View

13.

Rayman S, Almas K, Dincer E . Bisphosphonate-related jaw necrosis: a team approach management and prevention. Int J Dent Hyg. 2009; 7(2):90-5. DOI: 10.1111/j.1601-5037.2008.00331.x. View

14.

Hoff A, Toth B, Altundag K, Johnson M, Warneke C, Hu M . Frequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates. J Bone Miner Res. 2008; 23(6):826-36. PMC: 2677083. DOI: 10.1359/jbmr.080205. View

15.

Kourie H, Antoun J, El Rassy E, Rassy M, Sader-Ghorra C, Kattan J . Osteonecrosis of the jaw during biyearly treatment with zoledronic acid for aromatase inhibitor associated bone loss in early breast cancer: A literature review. J Bone Oncol. 2015; 4(3):77-9. PMC: 4648993. DOI: 10.1016/j.jbo.2015.09.001. View

16.

Hughes D, Wright K, Uy H, Sasaki A, Yoneda T, Roodman G . Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo. J Bone Miner Res. 1995; 10(10):1478-87. DOI: 10.1002/jbmr.5650101008. View

17.

Ito H, Matsuo K . Molecular epidemiology, and possible real-world applications in breast cancer. Breast Cancer. 2015; 23(1):33-38. DOI: 10.1007/s12282-015-0609-8. View

18.

Pilanci K, Alco G, Ordu C, Sarsenov D, Celebi F, Erdogan Z . Is administration of trastuzumab an independent risk factor for developing osteonecrosis of the jaw among metastatic breast cancer patients under zoledronic acid treatment?. Medicine (Baltimore). 2015; 94(18):e671. PMC: 4602532. DOI: 10.1097/MD.0000000000000671. View

19.

Ruggiero S, Mehrotra B, Rosenberg T, Engroff S . Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg. 2004; 62(5):527-34. DOI: 10.1016/j.joms.2004.02.004. View

20.

Sahni M, Guenther H, Fleisch H, Collin P, Martin T . Bisphosphonates act on rat bone resorption through the mediation of osteoblasts. J Clin Invest. 1993; 91(5):2004-11. PMC: 288198. DOI: 10.1172/JCI116422. View